The Pennsylvania-based company plans to initiate the randomized, controlled MAX-001-201 study in the coming months. MAX-001 functions as a triple monoamine re-uptake inhibitor, a mechanism currently unavailable in the U.S. for acute pain treatment. While nefopam has been prescribed internationally for decades, the Maxona formulation is designed specifically to provide rapid onset and sustained analgesia.
Maxona Pharmaceuticals Cleared for Phase 2 Acute Pain Study
The U.S. Food and Drug Administration has cleared Maxona Pharmaceuticals to begin Phase 2 clinical trials for MAX-001, an extended-release formulation of nefopam. This non-opioid, non-NSAID oral therapy aims to address the significant demand for effective pain management alternatives in the American market, targeting both acute and chronic conditions.
Previous Phase 1 testing, known as the MAX-001-101 trial, showed dose-proportional pharmacokinetics with no serious adverse events or premature discontinuations. According to Dr. Robert Rubens, the clinical development lead, the drug displayed a clean safety profile during initial testing. The upcoming Phase 2 trial will focus on gathering randomized, controlled data on post-surgical pain to further validate these findings.
Comments (0)
No comments yet. Be the first!